Skip to main content

Table 2 Treatment schedule and number of mice for each group

From: Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies

Group

Treatment

Number of mice

177Lu-TATE

TMZ

Control

–

Placebo

5

1: PRRT single

30 MBq day 0

Placebo

8

2: PRRT double

30 MBq day 0

Placebo

8

3: TMZ

–

50 mg/kg for 14 days from day 0

8

4: PRRT + TMZ at day 14

30 MBq day 0

50 mg/kg for 14 days from day 14

8

5: PRRT + TMZ

30 MBq day 0

50 mg/kg for 14 days from day 0

8

6: TMZ + PRRT at day 14

30 MBq day 14

50 mg/kg for 14 days from day 0

10

  1. 177 Lu-TATE lutetium-177-labelled octreotate, TMZ temozolomide, PRRT peptide receptor radionuclide therapy